Gregg McConnell
Corporate Officer/Principal chez TCR2 THERAPEUTICS INC.
Profil
Gregg McConnell is currently the Head of Business Development at TCR2 Therapeutics, Inc. He previously worked as the Senior Director of Worldwide Business Development at Pfizer Inc. and as the Vice President and Head of Business Development at BlueRock Therapeutics Canada ULC.
He received an undergraduate degree from Cornell University, an MBA from The Wharton School of the University of Pennsylvania, and a graduate degree from the Zanvyl Krieger School of Arts & Sciences.
Postes actifs de Gregg McConnell
| Sociétés | Poste | Début |
|---|---|---|
| TCR2 THERAPEUTICS INC. | Corporate Officer/Principal | 27/05/2020 |
Anciens postes connus de Gregg McConnell
| Sociétés | Poste | Fin |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
BlueRock Therapeutics Canada ULC
 BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Corporate Officer/Principal | - |
Formation de Gregg McConnell
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Cornell University | Undergraduate Degree |
| Zanvyl Krieger School of Arts & Sciences | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
BlueRock Therapeutics Canada ULC
BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Health Technology |
